Share-based Payment Arrangement, Expense in USD of Adverum Biotechnologies, Inc. from 2012 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Adverum Biotechnologies, Inc. quarterly and annual Share-based Payment Arrangement, Expense history and change rate from 2012 to Q3 2025.
  • Adverum Biotechnologies, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $2,349,000, a 21% decline year-over-year.
  • Adverum Biotechnologies, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $10,825,000, a 29% decline year-over-year.
  • Adverum Biotechnologies, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $14,350,000, a 18% decline from 2023.
  • Adverum Biotechnologies, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $17,569,000, a 13% decline from 2022.
  • Adverum Biotechnologies, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $20,079,000, a 20% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Adverum Biotechnologies, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $10,825,000 $2,349,000 -$615,000 -21% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $11,440,000 $2,423,000 -$1,522,000 -39% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $12,962,000 $2,778,000 -$1,388,000 -33% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $14,350,000 $3,275,000 -$873,000 -21% 01 Oct 2024 31 Dec 2024 10-K 15 Apr 2025 2024 FY
Q3 2024 $15,223,000 $2,964,000 -$1,425,000 -32% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $16,648,000 $3,945,000 -$524,000 -12% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q2
Q1 2024 $17,172,000 $4,166,000 -$397,000 -8.7% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q4 2023 $17,569,000 $4,148,000 -$1,105,000 -21% 01 Oct 2023 31 Dec 2023 10-K 15 Apr 2025 2024 FY
Q3 2023 $18,674,000 $4,389,000 -$114,000 -2.5% 01 Jul 2023 30 Sep 2023 10-Q 04 Nov 2024 2024 Q3
Q2 2023 $18,788,000 $4,469,000 -$473,000 -9.6% 01 Apr 2023 30 Jun 2023 10-Q 12 Aug 2024 2024 Q2
Q1 2023 $19,261,000 $4,563,000 -$818,000 -15% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $20,079,000 $5,253,000 +$843,000 +19% 01 Oct 2022 31 Dec 2022 10-K 18 Mar 2024 2023 FY
Q3 2022 $19,236,000 $4,503,000 -$823,000 -15% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $20,059,000 $4,942,000 -$3,292,000 -40% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $23,351,000 $5,381,000 -$1,843,000 -26% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $25,194,000 $4,410,000 -$1,767,000 -29% 01 Oct 2021 31 Dec 2021 10-K 30 Mar 2023 2022 FY
Q3 2021 $26,961,000 $5,326,000 -$694,000 -12% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $27,655,000 $8,234,000 +$3,449,000 +72% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $24,206,000 $7,224,000 +$3,815,000 +112% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q4 2020 $20,391,000 $6,177,000 +$3,327,000 +117% 01 Oct 2020 31 Dec 2020 10-K 29 Mar 2022 2021 FY
Q3 2020 $17,064,000 $6,020,000 +$3,359,000 +126% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021 2021 Q3
Q2 2020 $13,705,000 $4,785,000 +$2,159,000 +82% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $11,546,000 $3,409,000 +$1,647,000 +93% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q4 2019 $9,899,000 $2,850,000 +$1,669,000 +141% 01 Oct 2019 31 Dec 2019 10-K 01 Mar 2021 2020 FY
Q3 2019 $8,230,000 $2,661,000 -$335,000 -11% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $8,565,000 $2,626,000 -$3,200,000 -55% 01 Apr 2019 30 Jun 2019 10-Q 10 Aug 2020 2020 Q2
Q1 2019 $11,765,000 $1,762,000 -$1,667,000 -49% 01 Jan 2019 31 Mar 2019 10-Q 28 May 2020 2020 Q1
Q4 2018 $13,432,000 $1,181,000 -$703,000 -37% 01 Oct 2018 31 Dec 2018 10-K 01 Mar 2021 2020 FY
Q3 2018 $14,135,000 $2,996,000 +$296,000 +11% 01 Jul 2018 30 Sep 2018 10-Q 07 Nov 2019 2019 Q3
Q2 2018 $13,839,000 $5,826,000 +$3,583,000 +160% 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019 2019 Q2
Q1 2018 $10,256,000 $3,429,000 +$1,533,000 +81% 01 Jan 2018 31 Mar 2018 10-Q 08 May 2019 2019 Q1
Q4 2017 $8,723,000 $1,884,000 01 Oct 2017 31 Dec 2017 10-K 06 Mar 2019 2018 FY
Q3 2017 $2,700,000 -$242,000 -8.2% 01 Jul 2017 30 Sep 2017 10-Q 08 Nov 2018 2018 Q3
Q2 2017 $2,243,000 01 Apr 2017 30 Jun 2017 10-Q 08 Aug 2018 2018 Q2
Q1 2017 $1,896,000 -$2,188,000 -54% 01 Jan 2017 31 Mar 2017 10-Q 09 May 2018 2018 Q1
Q3 2016 $2,942,000 -$2,810,000 -49% 01 Jul 2016 30 Sep 2016 10-Q 08 Nov 2017 2017 Q3
Q1 2016 $14,816,000 $4,084,000 +$3,311,000 +428% 01 Jan 2016 31 Mar 2016 10-Q 06 May 2016 2016 Q1
Q4 2015 $11,505,000 $4,421,000 +$296,000 +7.2% 01 Oct 2015 31 Dec 2015 10-K 06 Mar 2018 2017 FY
Q3 2015 $11,209,000 $5,752,000 +$2,696,000 +88% 01 Jul 2015 30 Sep 2015 10-Q 09 Nov 2015 2015 Q3
Q2 2015 $8,513,000 $559,000 -$712,000 -56% 01 Apr 2015 30 Jun 2015 10-Q 13 Aug 2015 2015 Q2
Q1 2015 $9,225,000 $773,000 +$658,000 +572% 01 Jan 2015 31 Mar 2015 10-Q 06 May 2016 2016 Q1
Q4 2014 $8,567,000 $4,125,000 01 Oct 2014 31 Dec 2014 10-K 04 Mar 2016 2015 FY
Q3 2014 $3,056,000 +$2,943,000 +2604% 01 Jul 2014 30 Sep 2014 10-Q 09 Nov 2015 2015 Q3
Q2 2014 $1,271,000 +$1,152,000 +968% 01 Apr 2014 30 Jun 2014 10-Q 13 Aug 2015 2015 Q2
Q1 2014 $115,000 01 Jan 2014 31 Mar 2014 10-Q 13 May 2015 2015 Q1
Q3 2013 $113,000 01 Jul 2013 30 Sep 2013 10-Q 12 Nov 2014 2014 Q3
Q2 2013 $119,000 01 Apr 2013 30 Jun 2013 10-Q 12 Sep 2014 2014 Q2

Adverum Biotechnologies, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $14,350,000 -$3,219,000 -18% 01 Jan 2024 31 Dec 2024 10-K 15 Apr 2025 2024 FY
2023 $17,569,000 -$2,510,000 -13% 01 Jan 2023 31 Dec 2023 10-K 15 Apr 2025 2024 FY
2022 $20,079,000 -$5,115,000 -20% 01 Jan 2022 31 Dec 2022 10-K 18 Mar 2024 2023 FY
2021 $25,194,000 +$4,803,000 +24% 01 Jan 2021 31 Dec 2021 10-K 30 Mar 2023 2022 FY
2020 $20,391,000 +$10,492,000 +106% 01 Jan 2020 31 Dec 2020 10-K 29 Mar 2022 2021 FY
2019 $9,899,000 -$3,533,000 -26% 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2021 2020 FY
2018 $13,432,000 +$4,709,000 +54% 01 Jan 2018 31 Dec 2018 10-K 01 Mar 2021 2020 FY
2017 $8,723,000 -$2,693,000 -24% 01 Jan 2017 31 Dec 2017 10-K 06 Mar 2019 2018 FY
2016 $11,416,000 -$89,000 -0.77% 01 Jan 2016 31 Dec 2016 10-K 06 Mar 2018 2017 FY
2015 $11,505,000 +$2,938,000 +34% 01 Jan 2015 31 Dec 2015 10-K 06 Mar 2018 2017 FY
2014 $8,567,000 +$8,052,000 +1563% 01 Jan 2014 31 Dec 2014 10-K 04 Mar 2016 2015 FY
2013 $515,000 +$439,000 +578% 01 Jan 2013 31 Dec 2013 10-K 04 Mar 2016 2015 FY
2012 $76,000 01 Jan 2012 31 Dec 2012 10-K 05 Mar 2015 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.